<DOC>
	<DOCNO>NCT01602393</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ascend oral dos CHF 5074 prolong administration patient mild cognitive impairment .</brief_summary>
	<brief_title>Evaluation Safety &amp; Tolerability Multiple Dose Regimens CHF 5074 Exploration Effects Potential Markers Clinical Efficacy Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Diagnosis amnestic nonamnestic Mild Cognitive Impairment . MiniMental State Examination score high 24 screening . MRI scan brain screen fluidattenuation inversion recovery ( FLAIR ) T2*weighted gradientrecalledecho ( GRE ) sequence . Diagnosis Alzheimer 's disease accord ( DSMIVTR ) NINCDSADRDA criterion . Any medical condition could explain patient cognitive deficit . CT MRI brain imaging result obtain within 12 month prior baseline show evidence infection , infarction , focal lesion clinical significance MRI scan screen show 4 cerebral microhemorrhages ( lesion diameter â‰¤ 10 mm ) . Geriatric Depression Scale ( 30point scale ) score &gt; 9 screening . History stroke . Modified Hachinski ischemic scale score &gt; 4 screening . Women childbearing potential . Vitamin B12 folate deficiency . Diagnosis schizophrenia recurrent mood disorder ( include unipolar bipolar disorder ) within 3 year screen . Current diagnosis peptic ulcer gastrointestinal bleeding within last year and/or chronic inflammatory bowel disease . Concomitant use donepezil dose &gt; 5 mg/day cholinesterase inhibitor ( rivastigmine galantamine ) dose . Concomitant use memantine dose &gt; 20 mg/day . Concomitant use psychoactive drug ( sedative , hypnotic , etc ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>